CLINICAL STUDY SHOWS EPIFLO PROMOTES CHRONIC WOUND HEALING AND IMPROVES INFECTION CHARACTERISTICS

Ogenix, the developer and marketer of EPIFLO®, a breakthrough oxygen-generating device used for the treatment of chronic wounds, announced today the publication of the results of a human clinical pilot study by the American Professional Wound Care Association (APWCA). The study concluded that EPIFLO is an effective treatment for chronic wounds, promotes wound healing and reduces wound characteristics associated with infection.

The study treated 9 patients with chronic ulcers using EPIFLO® Transdermal Continuous Oxygen Therapy (TCOT) and measured progress over a period of 4 weeks. The study was led by Dr. Gary Sibbald, director of Wound Healing at the Women's College Hospital in Toronto and president of the World Union of Wound Healing Societies. The full text of the abstract can be found on the internet at http://ipwca.org/abstracts/abstract.cfm?ID=216

"The results of this study validate what Ogenix and its patients have known for years-that Transdermal Continuous Oxygen Therapy is an effective treatment for chronic wounds such as diabetic foot ulcers, venous ulcers, and pressure wounds" said Dr. Steve Berlin, Medical Director of Ogenix. "Further, the results are consistent with other recent studies and suggest that continuous oxygen treatment may be safer, more convenient, less expensive and equally or even more effective than Hyperbaric Oxygen Therapy."

About Ogenix

Ogenix is a medical device developer that manufactures and markets the EpiFLO®, a palm sized medical device used in sustained oxygen delivery for treatment of chronic wounds including diabetic foot ulcers, venous ulcers and pressure wounds. For additional information, please refer to their website at www.ogenix.com.